Daniel Pollyea, MD, MS, associate professor of medicine/hematology, and the clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia (AML).
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045